RecruitingNot Applicable

Pharmacogenomics of Heparin-Induced Thrombocytopenia

United States125 participantsStarted 2016-03

Plain-language summary

The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT * Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing Exclusion Criteria: * Less than 18 years of age * Pregnancy * Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw) * Known Human Immunodeficiency Virus (HIV) infection * Inability to give informed consent

What they're measuring

Serotonin Release Assay

Timeframe: 0-30 days

Heparin/platelet factor 4 antibody

Timeframe: 0-30 days

Trial details

NCT IDNCT02717039

SponsorUniversity of Arizona

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

Contact for this trial

Jason H Karnes, PharmD, PhD

520-626-1447 karnes@pharmacy.arizona.edu

View on ClinicalTrials.gov More Heparin-induced Thrombocytopenia trials